Claims for Patent: 8,080,534

Summary for Patent: 8,080,534

Title:	Targeting PAX2 for the treatment of breast cancer
Abstract:	The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the certain embodiments, the method of inhibiting expression of PAX2 is to administrate the subject a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 or by increasing expression of DEFB1 is also provided.
Inventor(s):	Donald; Carlton D. (Mount Pleasant, SC)
Assignee:	Phigenix, Inc (Atlanta, GA)
Application Number:	12/708,294
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,080,534
Patent Claims:	1. A method for treating a breast condition in a subject, comprising administering to a breast tissue of the subject, a composition that (1) inhibits PAX2 expression or PAX2 activity, (2) expresses DEFB1 or (3) inhibits PAX2 expression or PAX2 activity and expresses DEFB1. 2. The method of claim 1, wherein the breast condition is breast cancer or mammary intraepithelial neoplasia (MIN). 3. The method of claim 1, wherein said composition comprises a polynucleotide encoding an siRNA comprising a sequence selected from the group consisting of SEQ ID NOS: 3-6 and 11-15. 4. The method of claim 1, wherein said composition comprises a polynucleotide comprising SEQ ID NO:1 in forward or reverse orientation. 5. The method of claim 4, wherein said polynucleotide comprises the sequence of V-CCTTG-W, wherein V and W are contiguous nucleotide sequences of 1 to 35 nucleotides that flank the PAX2 binding site of DEFB1 promoter, and a complementary sequence thereof. 6. The method of claim 5, wherein said polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 18-21, 25, 26, 28 and 29. 7. The method of claim 1, wherein said composition comprises enalapril. 8. A method of treating breast cancer or MIN in a subject, comprising enhancing expression of DEFB1 in a breast cancer tissue or MIN tissue in the subject. 9. The method of claim 8, wherein the enhancing expression of DEFB1 comprises administering to the breast cancer tissue or MIN tissue in the subject an efficient amount of DEFB1. 10. The method of claim 8, wherein the enhancing expression of DEFB1 comprises administering to the breast cancer tissue or MIN tissue in the subject an efficient amount of an expression vector encoding DEFB1. 11. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-hormonal agent. 12. The method of claim 11, wherein the anti-hormonal agent is Tamoxifen. 13. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-ERBB-2 agent. 14. The method of claim 13, wherein the said anti-ERBB-2 agent is Herceptin. 15. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-Her-2 agent. 16. The method of claim 15, wherein the anti-Her-2 agent is Trastuzumab. 17. The method of claim 1, further comprising the step of: administering to the subject an effective amount of an anti-AIB-1/SRC-3 agent. 18. The method of claim 1, wherein said composition further comprises one or more agents selected from the group consisting of anti-hormanal agents, anti-ERBB-2 agents, anti-Her-2 agents, and anti-AIB-1/SRC-3 agent. 19. A method for treating a breast condition in a subject, comprising: (a) determining the PAX2-to-DEFB1 expression ratio in a diseased breast tissue from said subject; (b) determining the ER/PR status of said diseased breast tissue from said subject; and (c) based on the results of (a) and (b), administering to a breast tissue of said subject, a first composition that (1) inhibits PAX2 expression or PAX2 activity, (2) expresses DEFB1 or (3) inhibits PAX2 expression or PAX2 activity and expresses DEFB1. 20. The method of claim 19, wherein said breast condition is breast cancer or MIN. 21. The method of claim 19, wherein said first composition comprises a polynucleotide encoding an siRNA comprising a sequence selected from the group consisting of SEQ ID NOS: 3-6 and 11-15. 22. The method of claim 19, wherein said first composition comprises a polynucleotide comprising SEQ ID NO:1 in forward or reverse orientation. 23. The method of claim 22, wherein said polynucleotide comprises the sequence of V-CCTTG-W, wherein V and W are contiguous nucleotide sequences of 1 to 35 nucleotides that flank the PAX2 binding site of DEFB1 promoter, and a complementary sequence thereof. 24. The method of claim 23, wherein said polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 18-21, 25, 26, 28 and 29. 25. The method of claim 19, wherein said first composition comprises an antagonist selected from the group consisting of antagonists of angiotensin II, antagonists of angiotensin II receptor, antagonists of angiotensin-converting enzyme (ACE), antagonists of mitogen-activated protein kinase (MEK), antagonists of extracellular signal-regulated kinase 1,2 (ERK1,2), antagonists of signal transducer and activator of transcription 3 (STAT3). 26. The method of claim 19, wherein said first composition comprises a blocker of the RAS signaling pathway. 27. The method of claim 19, wherein said first composition is an anti-PAX2 agent conjugated to an antibody, a receptor or a ligand to target tumor tissue in said subject. 28. The method of claim 19, wherein said first composition is an anti-PAX2 agent comprising a small molecule that interferes or inhibits binding of PAX2 to the DEFB1 promoter. 29. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-hormonal agent. 30. The method of claim 29, wherein the anti-hormonal agent is Tamoxifen. 31. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-ERBB-2 agent. 32. The method of claim 31, wherein the anti-ERBB-2 agent is Herceptin. 33. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-Her-2 agent. 34. The method of claim 33, wherein the anti-Her-2 agent is Trastuzumab. 35. The method of claim 19, wherein the step (c) further comprises administering a second composition comprising an anti-AIB-1/SRC-3 agent.

Details for Patent 8,080,534

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-10-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-10-14
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2025-10-14